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ABSTRACT
Background The response to COVID-19 has required 
cancellation of all but the most urgent procedures; there 
is therefore a need for the reintroduction of a safe elective 
pathway.
Methods This was a study of a pilot pathway performed 
at Barts Heart Centre for the admission of patients 
requiring elective coronary and structural procedures 
during the COVID-19 pandemic (April–June 2020). All 
patients on coronary and structural waiting lists were 
screened for procedural indications, urgency and adverse 
features for COVID-19 prognosis and discussed at 
dedicated multidisciplinary teams. Dedicated admission 
pathways involving preadmission isolation, additional 
consent, COVID-19 PCR testing and dedicated clean areas 
were used.
Results 143 patients (101 coronary and 42 structural) 
underwent procedures (coronary angiography, 
percutaneous coronary intervention, transcatheter aortic 
valve intervention and MitralClip) during the study period. 
The average age was 68.2; 74% were male; and over 
93% had one or more moderate COVID-19 risk factors. All 
patients were COVID-19 PCR negative on admission with 
(8.1%) COVID-19 antibody positive (swab negative). All 
procedures were performed successfully with low rates 
of procedural complications (9.8%). At 2- week follow- 
up, no patients had symptoms or confirmed COVID-19 
infection with significant improvements in quality if life and 
symptoms.
Conclusion We demonstrated that patients undergoing 
coronary and structural procedures can be safely 
admitted during the COVID-19 pandemic, with no patients 
contracting COVID-19 during their admission. Reassuringly, 
patients reflective of typical practice, that is, those at 
moderate or higher risk, were treated successfully. This 
pilot provides important information applicable to other 
settings, specialties and areas to reintroduce services 
safely.
INTRODUCTION
The outbreak of the COVID-19 has affected 
nearly five million people worldwide, of 
which 319 960 have died as of 18 May 2020.1 
During the COVID-19 pandemic, pathways 
for treating cardiovascular disease have been 
disrupted, with elective activity discontinued 
to protect and reduce the risk to patients of 
contracting COVID-19. Additionally, there 
has been an expansion of high- dependency 
beds within hospitals, with the creation of 
‘COVID-19’ isolation wards and redistribu-
tion of resources to treat the influx of patients 
with COVID-19.2 Untreated patients with 
established cardiovascular disease are in high- 
risk categories (eg, severe aortic stenosis) and 
therefore are at risk of deterioration, resulting 
in emergency admission or sudden cardiac 
death. Emergency admission is likely to place 
the patient at increased risk of contracting 
Key questions
What is already known about this subject?
 ► COVID-19 has swept the world, resulting in a large 
number of deaths. Patients who have cardiovascular 
disease are a greater risk of mortality if contracting 
COVID-19. During the COVID-19 outbreak, there was 
a suspension of all elective activity both in cardiol-
ogy and other specialties. There was a need for the 
reintroduction of a safe pathway for elective patients 
who required both coronary and structural cardiac 
procedures.
What does this study add?
 ► This study demonstrated that the reintroduction of a 
specifically designed pathway that protects patients 
and reduces their risk of exposure to COVID-19 can 
be safely implemented, with no patients acquiring 
COVID-19 during their treatment.
How might this impact on clinical practice?
 ► This study has important implications for the rein-
troduction of elective services during and after the 
COVID-19 pandemic, both in patients with cardio-
vascular and other diseases requiring treatment. 
This is the first study to show that elective pro-
cedures can be safely provided with appropriate 
precautions.
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COVID-19. Delayed treatment will have consequences for 
recovery and long- term outcome in these patients, but 
many patients are appropriately deeply concerned about 
contracting COVID-19 in the hospital. These patients 
are also typically shielding, which may lead to delays in 
them seeking medical treatment with a reluctance to 
agree to admission even in the face of advanced symp-
toms and significant risk of clinical deterioration. There 
is therefore an imperative to maintain normal interven-
tional treatments particularly for patients with prognostic 
disease. With the relaxation in social isolation, a need for 
the reintroduction of pathways for the urgent treatment 
of appropriate high- risk patients on elective waiting lists 
is required and with it the essential need to minimise the 
risk of patients contracting COVID-19.
The aim of this study was to describe a pilot pathway 
to facilitate the admission of urgent elective cardiology 
patients for the treatment of cardiovascular disease 
while minimising the risks of exposing them to SAR- 
CoV-2 infection during the COVID-19 pandemic. The 
Figure 1 Patient flow diagram. MDT, multidisciplinary team; PROMS; Patient Reported Outcome Measures; QOL, quality of 
life.
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pathway integrated best practice recommendations 
available at the time of its conception and local expe-
riences of dealing with COVID-19 within the cardi-
ology and infective diseases departments. The pathway 
was proposed prior to the construction of the NHS 
England and NHS London ‘operating framework for 




All patients on cardiac interventional waiting lists 
between April and June 2020 at Barts Heart Centre, 
London, were included in this pilot. Each patient’s 
electronic medical records, referral, and angiographic 
and adjunctive imaging were reviewed by medical staff. 
All patients were then contacted to assess risk based on 
indications (ie, stable angina, severe aortic stenosis and 
medically managed acute coronary syndrome (ACS)), 
cardiac symptoms and patient- related adverse features for 
COVID-19 prognosis (age, renal function, gender, coex-
istent lung disease and Body Mass Index). Finally, it was 
discussed whether the patient was agreeable to attending 
during the pandemic. The patients were placed into 
three categories, depending on their urgency and risk 
profile (figure 1):
 ► Category 1: urgent (to be done as soon as able, ideally 
within 4–6 weeks).
 – Frequent symptoms on minimal exertion.
 – Significant worsening symptoms (Canadian 
Cardiovascular Society (CCS 3–4)).
 – Coronary anatomical risk—severe left main stent, 
proximal left anterior descending (LAD), three 
vessel disease.
 – Coronary bystander disease following ACS.
 – Medically managed non- ST segment elevation 
myocardial infarction (NSTEMI).
Table 1 Waiting list referrals
Total




Diagnostic angiogram 96 4 15 49 28
Left and right heart catheterisation 20 1 2 15 2
? Proceed 255 35 50 138 32
PCI 145 28 32 64 21
  Rotablation 2 1 1 0 0
  CTO 9 1 1 7 0
Structural Intervention
Alcohol septal ablation 1 0 0 1 0
Aortic coarctation 4 0 0 0 4
ASD closure 18 0 0 0 18
Balloon aortic valvuloplasty 1 0 0 1 0
Balloon mitral valvuloplasty 2 0 0 0 2
MitrClip 3 1 2 0 0
Paravalvular leak closure 3 1 0 0 2
PFO closure 109 0 0 109 0
Transcatheter valve implantation* 98 67 18 13 0
Total* 766 139 121 397 109
*All investigations complete.
ASD, atrial septal defect; CTO, chronic total occlusion; PCI, percutaneous coronary intervention; PFO, patent foramen ovale.
Figure 2 COVID-19 risk factors (combined coronary 
and structural patients). COVID-19 risk factors: age>70 
years, Body Mass Index>35, renal impairment (estimated 
glomerular filtration rate<60), cancer, BAME, black, Asian and 
minority ethnic.
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 – To facilitate non- cardiac emergency treatment 
(renal/oncology).
 ► Category 2: symptomatic on exertion but stable symp-
toms—to be done within 4 months.
 ► Category 3: stable long- standing symptoms—to be 
done within 6 months.
Multidisciplinary team (MDT)
All category 1 patients were reviewed in a virtual MDT 
meeting (containing interventional consultants and cardi-
othoracic surgeons if surgical revascularisation options 
would need to be discussed). This was performed using 
an online video conferencing system (StarLeaf, Watford, 
Hertfordshire). The MDT reviewed the patient’s risk/
urgency to ensure category 1 status and then weighed up 
the benefit for the patient to undergo coronary or struc-
tural intervention against the potential risk of a day case 
admission during a pandemic. Patients were then listed 
in consensus was agreed on the above.
Preassessment
For infection control purposes, all preassessment appoint-
ments were held over the telephone. Patients were 
further screened for COVID-19 symptoms and exposure 
at that stage and underwent a standard preassessment 
consultation. Patients were informed they would have 
to self- isolate at home for 2 weeks prior to admission. A 
final preadmission check was performed by an advanced 
clinical practitioner, 24 hours prior to admission to assess 
for COVID-19 symptoms (cough, fever and new loss of 
sense of smell (anosmia)), confirming isolation and 
checking for new potential COVID-19 exposure. At this 
stage, a further discussion about the risks and benefits 
of attending during the pandemic was held with the 
patient to ensure their understanding of potential addi-
tional risk of contracting COVID-19 while in the hospital. 
This process was standardised for all patients, covering 
the risk of contracting COVID-19 during the admission 
and the means to reduce this risk. If patients agreed, this 
was documented in their electronic medical records, 
with them given a copy on the day of admission. If all the 
aforementioned were satisfied, patients were admitted 
the following day, with second consent performed for the 
procedure via standard trust consent forms.
Admission
All patients were met on admission, given a face mask and 
escorted to a side room on a clean (COVID-19- free) ward. 
No relatives were allowed to accompany the patient. On 
arrival on the ward, patients were swabbed for COVID-
19; staff contact was minimised; and all patient- to- staff 
contact was made using standard local personal protec-
tive equipment guidelines. Patients undergoing percu-
taneous coronary intervention (PCI) procedures were 
loaded with 600 mg clopidogrel and 300 mg aspirin on 
the morning, depending on pre- existing medication. 
Blood tests were performed on the day of the procedure 
Table 2 Coronary intervention patient demographics
n=101
Age (year), mean±SD 62.29±10.12
Male sex, n (%) 84 (83.2)
Black, Asian, minority ethnic, n (%) 58 (57.4)
Median BMI (IQR) 27.55 (25.14–29.39)
Medical history, n (%)
  Hypertension 55 (54.4)
  Hypercholesterolaemia 62 (61.4)
  Diabetes mellitus 31 (30.7)
  Smoking history 20 (19.8)
  Previous MI 31 (30.7)
  Previous PCI 41 (40.6)
  Previous CABG 9 (8.9)
LV ejection fraction (%), mean±SD 53.70±7.27
Serum creatinine (μmol/L), mean±SD 83.86±16.33
Elective procedure, n (%) 72 (71.3)
Staged procedure following ACS, n (%) 18 (17.8)
Angiogram±PCI for medically managed ACS 11 (10.9)
Femoral access, n (%) 15 (14.9)
Procedural type, n (%)
Diagnostic angiogram, n (%) 33 (32.7)
  Medical management—no planned interventions 12 (36.4)
  Workup for valve surgery 1 (3)
  Investigations of troponin- positive events 3 (9.1)
  Other surgery 3 (9.1)
  Planned for staged PCI 3 (9.1)
  Referral for CABG/MDT 11 (33.3)
Diagnostic device used, no therapeutic intervention n (%) 14 (13.9)
PCI, n (%) 54 (54.5)
  left anterior descending artery 31 (57.4)
  Left circumflex 23 (42.6)
  Right coronary artery 12 (22.2)
  Grafts 2 (3.7)
  Diagnostic device used to guide PCI 31 (57.4)
  Functional indices (FFR/iFR) 5 (16.1)
  Intravascular ultrasound 24 (77.4)
  Optical coherence tomography 2 (6.4)
Procedural complexity
Multivessel PCI 11 (20.4)
Number of stents used, mean±SD 1.47±0.79
Length of segment treated (mm), mean±SD 41.63±20.9
Bifurcation, n (%) 8 (14.8)
Instent restenosis, n (%) 4 (7.4)
CTO, n (%) 4 (7.4)
Calcium modification, n (%) 4 (7.4)
  Rotational atherectomy 3 (5.6)
  Intravascular llthotripsy 1 (1.9)
ACS, acute coronary syndrome; BMI, Body Mass Index; CABG, coronary 
artery bypass; LV, left ventricle; MDT, multidisciplinary team; MI, myocardial 
infarction; PCI, percutaneous coronary intervention.
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using point- of- care testing. The patients underwent their 
procedure in a cardiac catheter lab and were transferred 
to and from the ward via a designated clean transfer 
route. They were subsequently discharged as per routine 
cardiology intervention practice. Patients were contacted 
1 and 2 weeks postprocedure to assess for COVID-19 
status, clinical events (MACE) and quality of life (QOL).
RESULTS
Patient population
A total of 766 elective patients were reviewed up to 30 
June 2020. Of these patients, 527 (68.8%) were referred 
for coronary procedures and 239 patients were awaiting 
a structural procedure. The classification breakdown of 
telephone assessment can be seen as follows (table 1); 
a total of 109 (14.2%) were uncontactable during these 
phone consultation. Of the 527 patients who under-
went elective coronary procedure, 132 were discussed in 
virtual MDT, with 1 patient being excluded due to clin-
ical indication for angiography. In the structural group, 
80 patients were discussed, with 13 patients excluded as 
being symptom free at the time of the review.
COVID-19
All patients were screened for COVID-19 PCR on 
admission, although two swabs were lost in transit 
to the lab and were not processed. All of the 143 
Table 3 COVID-19 screening and admission 









  MDT discussion 101 (100) 42 (100)
  Self- Isolation 98 (97.0) 41 (97.6)
  Key worker 2 (2.1) 0 (0)
Admission
  Isolated on ward 81 (80.2) 42 (100)
  Stay over 24 hours 2 (2.1) 2 (2)
  Overnight stay 1 (1) 32 (78)
  2 days–1 week 0 (0) 5 (12.2)
  Greater than 1 week 1 (1) 4 (9.8)
Brought back for physical review 
within 30 days
3 (3) 0 (0)
Week 2 health questionnaire (EQ5D)
  Mobility 1.75 (0.99) –
  Self- care 1.45 (0.85) –
  Usual activities 1.73 (0.98) –
  Pain 1.745 (1.03) –
  Anxiety/depression 1.54 (0.83) –
  Total score 73.30±21.93 –




Swab or antibody+ve prior to 
admission
1 (1) 0 (0)
Admission investigations
  Swab+ve on admission 0 (0) 0 (0)
  Antibody tests on admission 36 (36%) 1 (3.2)
  Antibody+ve on admission 3 (8.3%) 0 (0)
  Symptoms postdischarge 0 (0) 1 (3.2)
MDT, multidisciplinary team; +ve, positive.
Table 4 Structural intervention patient demographics
Elective 
structural (n=42)
Age (year), mean±SD 80.90±5.92
Male sex, n (%) 22 (52.4)
Black, Asian, minority ethnic, n (%) 4 (9.5)
Height (cm), mean±SD 165.51±9.90
Weight (kg), mean±SD 75.02±11.00
Median body surface area (m2) (IQR) 1.81 (1.71–1.95)
Median BMI (IQR) 26.7 (25.04–31.16)
CCS (II–III) 2 (4.8)
NYHA (III–IV) 30 (71.4)
Medical history, n (%)
  Hypertension 22 (52.4)
  Hypercholesterolaemia 7 (16.7)
  Diabetes mellitus 9 (21.4)
  IHD (PCI/CABG/MI) 28 (66.7)
  Chronic kidney disease 8 (19.0)
Serum creatinine (μmol/L), mean±SD 109.74±63.89
LV ejection fraction 53.98±10.45
AVA (cm2) 0.68±0.18
Peak velocity (ms) 4.24±0.61
Procedural type, n (%)
  TAVI 39 (92.9)
  Pulmonary artery intervention 0 (0)
  MitraClip 2 (4.8)
  Paravalvular leak closure device 1 (2.4)
Complications, n (%) 8 (18.2)
  Permanent pacing 4 (50)
  Emergency valve surgery 1 (12.5)
  Femoral complication 2 (25)
  Myocardial infarction 1 (12.5)
  Pulmonary oedema 1 (12.5)
AVA, aortic valve area; BMI, Body Mass Index; CCS, Canadian 
Cardiovascular Society; LV, left ventricular; MI, myocardial 
infarction; NYHA, New York Heart Association; PCI, percutaneous 
coronary intervention; TAVI, transcatheter aortic valve intervention.
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patients with tested samples were PCR swab negative. 
COVID-19 antibody testing became available on 8 June 
2020 with 37 subsequent patients tested on admission. 
Of these 37 patients, 8.1% (3 patients) were antibody 
positive (but were all swab negative on admission). 
All of the positive patients had COVID-19 symptoms 
in the last few months following A+E attendances at 
district general hospitals due to chest pain. In terms of 
COVID-19 risk, over 93% had one or more moderate 
risk factors, with the breakdown shown in figure 2.
Elective coronary procedures
A total of 125 coronary patients were scheduled 
for admission between 20 April 2020 and 19 June 
2020, with 22 patients cancelled preadmission (1 
due to exposure to COVID-19, 6 declined admission 
following discussion regarding COVID-19 risk, 7 due 
to clinical reasons, 3 presented acutely as ACS and 
6 declined the TCI (to come in) date). In total, 101 
patients were admitted for coronary procedures (3 
having two procedures during the time frame), with 
the baseline demographic and procedural informa-
tion for these patients shown in table 2. All patients 
had been discussed in the virtual MDT prior to admis-
sion; three patients did not fully self- isolate prior 
to admission (two were key workers and one had a 
previous COVID-19+ swab (3 months earlier) prior to 
admission and declined to self- isolate).
The indication for the procedure was angina in 
71.3% of the patients and staged procedure following 
ACS in 17.8% and 10.9% of the patients were 
following an initially medically managed ACS. Fifty- 
four patients (54.5%) underwent PCI with a total 
of 33 patients undergoing diagnostic angiography 
with the remaining 31 cases using diagnostic devices 
to facilitate coronary intervention. There were only 
four immediate procedural complications, three 
haematomas and one coronary dissection. Ninety- 
eight patients (94.2%) were discharged on the same 
day with 6 (5.8%) having overnight stays due to coro-
nary dissection,4 vascular complications,5 observation 
post- CTO6 and for urgent CABG4 (table 3).
Elective structural procedures
A total of 42 patients underwent urgent elective 
structural procedures, with 39 patients undergoing 
transcatheter aortic valve intervention, 2 under-
going MitraClip and 1 undergoing paravalvular leak 
closure. The baseline demographics and procedural 
information for these patients can be seen in table 4 
and admission in table 3. Eight patients had complica-
tions during structural procedure, with four patients 
requiring urgent pacing, one requiring urgent valve 
surgery and two with femoral access complications. 
The majority of patients had one night admission with 




One- week telephone follow- up was performed for 
the first 39 patients but was stopped after this due to 
time restraints and increased elective admissions. No 
patients had COVID-19 symptoms at that point. At 
2 weeks of follow- up, all patients had no symptoms of 
COVID-19, with no confirmed COVID-19 cases. QOL 
was recorded for 97 patients, with a mean EQ5D- VAS 
of 73.5±19.8 (range 30–100). No MACE events were 
recorded during the 2- week follow- up period (0%).
Structural
At 2 week of follow- up, one patient reported a fever 
but was COVID-19 swab negative and was treated for a 
community acquired chest infection by their GP. One 
patient was admitted to the hospital for non- cardiac 
issues and three patients reported worsening lethargy 
postprocedure; however, 14 patients (45%) noticed 
immediate improvement in symptom benefit.
DISCUSSION
The reintroduction of a safe elective pathway to facil-
itate the treatment of cardiovascular disease is para-
mount in the current COVID-19 pandemic.6 In this 
pilot study, we have demonstrated that patients can 
be brought in safely for urgent elective interventional 
procedures to a centre where COVID-19- positive 
patients are also being managed. Measures such as 
effective case triaging, thorough history taking and 
patient screening, periods of self- isolation and careful 
well- planned pathways within the hospital, including 
designated COVID-19- free areas, meant that all 
patients were treated without contracting COVID-19 
infection. The hiatus of elective waiting lists can lead 
to increased stress and anxiety for patients or can 
result in acute care hospital admissions, meaning 
increased risk of COVID-19 exposure.5 Importantly, 
this pathway provides an effective solution to this clin-
ical need in the current climate for patients who are 
happy to attend after being adequately informed and 
formally consenting to COVID-19 risk.
A key aspect of the pathway was to minimise patient 
hospital time and visits, that is, telephonic preadmis-
sion, point- of- care blood testing, on- the- day swabs/
drug loading and minimising length of stay, all to 
reduce possible COVID-19 exposure. The coronary 
interventional patients had on average less than 12 
hours’ stay within the hospital, with the structural 
patients staying just over 24 hours within the hospital 
with the majority discharged on day 2. However, 
despite these protocols developed to minimise the 
risk of COVID-19 transmission, the risk cannot be 
completely eliminated. It is imperative for additional 
risk of contracting COVID-19 to be highlighted and 
for this to be formally documented in the consenting 
process.
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One issue with this pathway is the timing and use 
of nasal swab for preprocedural testing rather than 
antibody testing. Establishing COVID-19 status by 
nasopharyngeal swab was essential to manage patients 
staying overnight in appropriate areas within the 
hospital. There were only small numbers of coronary 
patients requiring admission overnight, but this was 
standard practice for structural cases. However, swab 
results were not available during admission or often 
predischarge. Antibody testing was introduced in 
the interventional group after 64 patients, with only 
around 8% of patients having positive results. With 
the introduction of antibody testing nationwide, there 
may be a role for these tests (swab and antibody) to be 
done prior to admission to assess patients’ COVID-19 
status prior to their procedure. Despite no swabbing 
being undertaken preprocedure, not a single patient 
was COVID-19 positive on admission, highlighting 
the robustness of our 2- week isolation and screening 
questionnaires. However, aspects of this pathway, 
although essential at the time, are difficult to main-
tain as normal service slowly resumes. Isolation for 
2 weeks prior to admission was straightforward with 
the majority of cardiac patients shielding. However, 
the psychological effects of lockdown especially in the 
elderly population has been well documented,7 and 
as this is relaxed on a population level, it is likely that 
the pathway will need to evolve, for example, 7 days 
of self- isolation with routine PCR swapping preproce-
dure (1–3 days).
It is natural that both cardiologists and patients are 
apprehensive about restarting elective services, with 
one of the biggest challenges among patients awaiting 
elective procedures being the fear of contracting 
COVID-19. Some studies have reported up to 50% of 
patients awaiting orthopaedic procedures, wanting to 
wait until postpandemic, although no data exists for 
elective cardiac procedures.4 In our pathway, the use 
of cardiologists and advanced nurse practitioners to 
assess and contact patients resulted in correct patient 
identification and reassurance to these patients 
rather than clerical staff. In addition, the allocation 
of a single dedicated allied nurse professional to lead 
the admission and follow- up improved patient care 
and reassurance. In many cases, issues were identified 
in follow- up that helped expedite or facilitate patient 
care postprocedure, all of which were an inevitable 
consequence of reduced services during a pandemic, 
that is, availability of cardiac rehabilitation.
It is known that patients with pre‐existing cardio-
vascular disease are likely to have comorbidities 
which are associated with poorer clinical outcomes 
in confirmed SARS‐CoV‐2 cases.89 Additionally the 
majority (>90%) of patients treated had one or more 
moderate adverse features, in addition to cardiac 
disease such as age over >70 years or renal dysfunc-
tion, a truly reflective population of those requiring 
treatment. Despite this risk, no patient reported 
COVID-19- like symptoms postadmission at the 2- week 
follow- up with no confirmed cases and no adverse 
cardiac events. Importantly, at this point, a significant 
increase in QOL was also seen despite the ongoing 
pandemic, highlighting the importance of reintro-
ducing these services. As we have demonstrated this 
safe pathway for cardiovascular patients, this can be 
used as a blueprint for the reintroduction of other 
importance elective treatments, that is, orthopaedic 
surgery.
CONCLUSION
Restarting elective cardiac services during the 
COVID-19 pandemic is essential, given the burden 
of disease and its potential impact. This pilot demon-
strates that with careful planning and structured 
protocols, interventional cardiac procedures can be 
safely delivered with no patient developing COVID-19 
infection, despite high- risk features in the patient 
cohort. Despite the risks being minimised, they 
cannot be completely eliminated, and it is imperative 
patients are counselled and consented formally prior 
to their procedures.
Twitter Michael Mullen @bartstrctural
Acknowledgements We acknowledge the cardiology advanced clinical 
practitioners (Oliver Casey- Gillman and Lizzie Moore), the transcatheter aortic 
valve intervention specialist nurses (Helen Queenan, Melanie Jerrum and Kerry 
Bedford) and the Cath Lab management team (Rob Hall and Simon Cook) for their 
contribution to the pilot. Finally, we thank all the staff of Barts Heart Centre for their 
hard work and professionalism during the COVID-19 outbreak, and for the NHS 
patients who have been very supportive throughout this difficult time.
Contributors Planning: SH, GM, GF, JL, AM and DJ. Conduct: SH, KC, FC, KR, MA, 
AW, MO, OG, MM, AB, ES, AM and DJ. Overall content: SH, AM and DJ.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval Local discussion within the Barts Health NHS Trust was 
performed prior to the initiation of the programme.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Stephen Hamshere http:// orcid. org/ 0000- 0002- 8823- 1019
Michael Mullen http:// orcid. org/ 0000- 0002- 4911- 3511
REFERENCES
 1 Dashboard. WHOCOVID.
 2 Wu Z, McGoogan JM. Characteristics of and Important Lessons 
From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: 
Summary of a Report of 72 314 Cases From the Chinese Center for 
Disease Control and Prevention. JAMA 2020;323:1239-1242.
 3 England NHS. Operating framework for urgent and planned services 
in hospital settings during COVID-19.
Open Heart
8 Hamshere S, et al. Open Heart 2021;8:e001446. doi:10.1136/openhrt-2020-001446
 4 Chang J, Wignadasan W, Kontoghiorghe C, et al. Restarting elective 
orthopaedic services during the COVID-19 pandemic. Bone Jt Open 
2020;1:267–71.
 5 da Fonseca VBP, De Lorenzo A, Tura BR, et al. Mortality and morbidity 
of patients on the waiting list for coronary artery bypass graft surgery. 
Interact Cardiovasc Thorac Surg 2018;26:34–40.
 6 Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular 
disease. Circulation 2020;141:1648–55.
 7 Plagg B, Engl A, Piccoliori G, et al. Prolonged social isolation of the 
elderly during COVID-19: between benefit and damage. Arch Gerontol 
Geriatr 2020;89:104086.
 8 Khan IH, Zahra SA, Zaim S, et al. At the heart of COVID-19. J Card 
Surg 2020;35:1287–94.
 9 W- j G, W- h L, Zhao Y. Comorbidity and its impact on 1590 patients 
with COVID-19 in China: a nationwide analysis. European Respiratory 
Journal Eur Respir J 2020;55:2000547.
